Literature DB >> 20471712

TTF-1 mRNA-positive circulating tumor cells in the peripheral blood predict poor prognosis in surgically resected non-small cell lung cancer patients.

Sun Och Yoon1, Young Tae Kim, Kyeong Cheon Jung, Yoon Kyung Jeon, Baek-Hui Kim, Chul-Woo Kim.   

Abstract

Circulating tumor cells (CTCs) have been identified in peripheral blood of cancer patients, and reproducible detection of CTCs has demonstrated the potential as useful diagnostic and prognostic tools in several cancers. Present study aimed to determine the clinical relevance of CTCs in surgically resected non-small cell lung cancer (NSCLC) patients. CTC status in presurgery and postsurgery peripheral blood samples from 79 surgically resected NSCLC patients was investigated using thyroid transcription factor-1 (TTF-1) and cytokeratin19 (CK19) mRNA markers by nested real-time RT (reverse transcription)-PCR assay. Detection of TTF-1((+))CTCs was found to be specific to NSCLC patients. TTF-1((+))CTCs were detected in 36.1% (22/61) of patients before surgery and in 37.5% (18/48) after surgery. For CK19 mRNA-expressing CTCs (CK19((+))CTCs), the detection rate was 42.6% (26/61) before surgery, and 25.0% (12/48) after surgery. Cases with postsurgery TTF-1((+)) and/or CK19((+))TCs was more associated with disease progression (P=0.004) and shorter disease progression-free survival (P=0.006) as compared to those without postsurgery CTCs. As an individual marker, postsurgery TTF-1((+))CTCs-positive status was more associated with disease progression (P=0.004) and shorter disease progression-free survival (P=0.004) as compared to postsurgery TTF-1((+))CTCs-negative status. Particularly, patients with postsurgery TTF-1((+))CTCs, but not presurgery (Pre((-))Post((+)) cases) showed marked shorter disease progression-free survival than other patients (P<0.001). On the other hand, a CK19((+))CTC status individually did not show significant clinical relevance, and presurgery CK19((+))CTC status did not either. Present study suggests that TTF-1 mRNA-expressing CTCs might be a useful surrogate predictor of disease progression before clinical manifestations are apparent, and that monitoring of TTF-1((+))CTCs status after surgery may be useful for identifying high-risk patients among surgically resected NSCLC cases. Copyright Â
© 2010 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471712     DOI: 10.1016/j.lungcan.2010.04.017

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  32 in total

Review 1.  Clinical utility of circulating tumour cell detection in non-small-cell lung cancer.

Authors:  Alberto Fusi; Robert Metcalf; Matthew Krebs; Caroline Dive; Fiona Blackhall
Journal:  Curr Treat Options Oncol       Date:  2013-12

Review 2.  Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring.

Authors:  David Pérez-Callejo; Atocha Romero; Mariano Provencio; María Torrente
Journal:  Transl Lung Cancer Res       Date:  2016-10

Review 3.  Clinical utility of circulating tumor cells in patients with non-small-cell lung cancer.

Authors:  Marianna Gallo; Antonella De Luca; Monica Rosaria Maiello; Amelia D'Alessio; Claudia Esposito; Nicoletta Chicchinelli; Laura Forgione; Maria Carmela Piccirillo; Gaetano Rocco; Alessandro Morabito; Gerardo Botti; Nicola Normanno
Journal:  Transl Lung Cancer Res       Date:  2017-08

4.  Detection of circulating tumor cells: Clinical relevance of a novel metastatic tumor marker.

Authors:  Chuanli Ren; Chongxu Han; Daxin Wang; Xiaohang Zhao; Guangfu Jin; Hongbing Shen
Journal:  Exp Ther Med       Date:  2011-03-21       Impact factor: 2.447

Review 5.  Circulating tumors cells as biomarkers: progress toward biomarker qualification.

Authors:  Daniel C Danila; Klaus Pantel; Martin Fleisher; Howard I Scher
Journal:  Cancer J       Date:  2011 Nov-Dec       Impact factor: 3.360

Review 6.  Circulating tumor cells in lung cancer: detection methods and clinical applications.

Authors:  Na Yu; Jia Zhou; Fang Cui; Xiaokui Tang
Journal:  Lung       Date:  2015-02-19       Impact factor: 2.584

Review 7.  Prognostic and predictive biomarkers in early stage NSCLC: CTCs and serum/plasma markers.

Authors:  Philip A J Crosbie; Rajesh Shah; Yvonne Summers; Caroline Dive; Fiona Blackhall
Journal:  Transl Lung Cancer Res       Date:  2013-10

8.  Prognostic value of cytokeratin-7 mRNA expression in peripheral whole blood of advanced lung adenocarcinoma patients.

Authors:  Ana Koren; Eva Sodja; Matija Rijavec; Mojca Jez; Viljem Kovac; Peter Korosec; Tanja Cufer
Journal:  Cell Oncol (Dordr)       Date:  2015-08-26       Impact factor: 6.730

Review 9.  Nkx2-1: a novel tumor biomarker of lung cancer.

Authors:  Li Yang; Min Lin; Wen-jing Ruan; Liang-liang Dong; En-guo Chen; Xiao-hong Wu; Ke-jing Ying
Journal:  J Zhejiang Univ Sci B       Date:  2012-11       Impact factor: 3.066

10.  Prognostic value of EpCAM/MUC1 mRNA-positive cells in non-small cell lung cancer patients.

Authors:  Wen-Fang Zhu; Jian Li; Li-Chao Yu; Yian Wu; Xin-Ping Tang; Yi-Ming Hu; Yong-Chang Chen
Journal:  Tumour Biol       Date:  2013-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.